|
1
|
Silva R: Myopic maculopathy: A review.
Ophthalmologica. 228:197–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sawada A, Tomidokoro A, Araie M, Iwase A
and Yamamoto T: Tajimi Study Group: Refractive errors in an elderly
Japanese population: The Tajimi study. Ophthalmology. 115:363–370.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheng CY, Hsu WM, Liu JH, Tsai SY and Chou
P: Refractive errors in an elderly Chinese population in Taiwan:
The Shihpai Eye Study. Invest Ophthalmol Vis Sci. 44:4630–4638.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenfeld PJ, Brown DM, Heier JS, et al:
MARINA Study Group: Ranibizumab for neovascular age-related macular
degeneration. N Engl J Med. 355:1419–1431. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pece A, Vadalà M, Isola V and Matranga D:
Photodynamic therapy with verteporfin for juxtafoveal choroidal
neovascularizzation in pathologic myopia: A long-term follow-up
study. Am J Ophthalmol. 143:449–454. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martin DF, Maguire MG, Ying GS, Grunwald
JE, Fine SL and Jaffe GJ: CATT Research Group: Ranibizumab and
bevacizumab for neovascular age-related macular degeneration. N
Engl J Med. 364:1897–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gharbiya M, Allievi F, Mazzeo L and
Gabrieli CB: Intravitreal bevacizumab treatment for choroidal
neovascularization in pathologic myopia: 12-month results. Am J
Ophthalmol. 147:84–93, e1. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vadalà M, Pece A, Cipolla S, et al: Is
ranibizumab effective in stopping the loss of vision for choroidal
neovascularisation in pathologic myopia? A long-term follow-up
study. Br J Ophthalmol. 95:657–661. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Otsuka K, Imai H, Shimoyama T, Nagai T,
Honda S and Azumi A: Recurrence of macular hole retinal detachment
after intravitreal ranibizumab injection for the treatment of
choroidal neovascularization from the remaining macular hole edge.
Case Rep Ophthalmol. 3:424–427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lorenzo D, Arias L, Alcubierre R, et al:
Intravitreal ranibizumab for choroidal neovascularization secondary
to pathological myopia: 12-month follow-up. Ophthalmologica.
226:103–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshida T, Ohno-Matsui K, Yasuzumi K, et
al: Myopic choroidal neovascularization: A 10-year follow-up.
Ophthalmology. 110:1297–1305. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hayashi K, Shimada N, Moriyama M, Hayashi
W, Tokoro T and Ohno-Matsui K: Two-year outcomes of intravitreal
bevacizumab for choroidal neovascularization in Japanese patients
with pathologic myopia. Retina. 32:687–695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wakabayashi T, Ikuno Y and Gomi F:
Different dosing of intravitreal bevacizumab for choroidal
neovascularization because of pathologic myopia. Retina.
31:880–886. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mateo C, Moreno J, Rosales G, et al:
Two-year results of macular translocation with scleral infolding in
myopic choroidal neovascularisation. Semin Ophthalmol. 19:29–42.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ladas ID, Moschos MM, Rouvas AA,
Karagiannis DA and Kokolakis SN: Lacquer crack formation after
photodynamic therapy. Eur J Ophthalmol. 13:729–733. 2003.PubMed/NCBI
|
|
16
|
Ferrara N, Damico L, Shams N, Lowman H and
Kim R: Development of ranibizumab, an anti-vascular endothelial
growth factor antigen binding fragment, as therapy for neovascular
age-related macular degeneration. Retina. 26:859–870. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Wiesmann C, Fuh G, et al:
Selection and analysis of an optimized anti-VEGF antibody: Crystal
structure of an affinity-matured Fab in complex with antigen. J Mol
Biol. 293:865–881. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krzystolik MG, Afshari MA, Adamis AP, et
al: Prevention of experimental choroidal neovascularization with
intravitreal anti-vascular endothelial growth factor antibody
fragment. Arch Ophthalmol. 120:338–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Figurska M and Stankiewicz A: Anti-VEGF
therapy in the treatment of myopic macular choroidal
neovascularization - case report. Klin Oczna. 110:387–391. 2008.(In
Polish). PubMed/NCBI
|
|
20
|
Ng DS, Kwok AK and Chan CW: Anti-vascular
endothelial growth factor for myopic choroidal neovascularization.
Clin Experiment Ophthalmol. 40:e98–e110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu TT and Kung YH: The 12-month outcome of
three consecutive monthly intravitreal injections of ranibizumab
for myopic choroidal neovascularization. J Ocul Pharmacol Ther.
28:129–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lai TY, Chan WM, Liu DT and Lam DS:
Intravitreal ranibizumab for the primary treatment of choroidal
neovascularization secondary to pathologic myopia. Retina.
29:750–756. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Calvo-Gonzalez C, Reche-Frutos J, Donate
J, Fernandez-Perez C and Garcia-Feijoo J: Intravitreal ranibizumab
for myopic choroidal neovascularization: Factors predictive of
visual outcome and need for retreatment. Am J Ophthalmol.
151:529–534. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neelam K, Cheung CM, Ohno-Matsui K, Lai TY
and Wong TY: Choroidal neovascularization in pathological myopia.
Prog Retin Eye Res. 31:495–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
